Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - indometacin - modified-release capsule - 75mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - indometacin - oral capsule - 25mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - indometacin - oral capsule - 50mg

Malta - Kiingereza - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - indometacin - hard capsule - indometacin 25 mg - antiinflammatory and antirheumatic products

Malta - Kiingereza - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - indometacin - capsule - indometacin 25 mg - antiinflammatory and antirheumatic products

Malta - Kiingereza - Medicines Authority

drossapharm gmbh wallbrunnstrasse 24 79539 lörrach, germany - acemetacin - hard capsule - acemetacin 60 mg - antiinflammatory and antirheumatic products

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - indometacin - oral capsule - 25mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - indometacin - oral capsule - 25mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - indometacin - oral capsule - 25mg

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; indigo carmine; purified water; sorbitan monolaurate; erythrosine; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; brilliant blue fcf; butan-1-ol; quinoline yellow; allura red ac; sd alcohol 45; sd alcohol 3-a - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease